Mather Group
SYRE icon

Mather Group’s Spyre Therapeutics SYRE Stock Holding History

Mather Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.58K Buy
+29
New +$2.79K ﹤0.01% 1985

Other funds holding SYRE

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
HIA
Harbor Investment Advisory Lutherville, Maryland $1.47B AUM 24.2% 1-Year Est. Return
CIA
Cape Investment Advisory Mcdonough, Georgia $388M AUM 17.15% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Mather Group's SYRE Position: Q3 2026 in Review

Mather Group opened a new position in Spyre Therapeutics (SYRE) in Q3 2026: 29 shares worth $2.58K. The stake represents ﹤0.01% of the portfolio and ranks #1985 among its holdings.

7 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.

  • Mather Group held 29 shares of Spyre Therapeutics worth $2.58K as of Q3 2026.
  • Spyre Therapeutics was a new Mather Group position in Q3 2026.
  • Spyre Therapeutics made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #1985 holding.
  • 7 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.